Evidence map›Paper›PMID 36169886›Full record

ArticleWorld journal of pediatrics : WJP2022

Variation in SARS-CoV-2 seroprevalence in children in the region of Asturias, Northern Spain.

Elisa García-García, Mercedes Rodríguez-Pérez, David Pérez-Solís, Carlos Pérez-Méndez, Cristina Molinos-Norniella, Ángeles Cobo-Ruisánchez, Eva María Fernández Fernández, Noelia García González, Laura Calle-Miguel

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in World journal of pediatrics : WJP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Elisa García-GarcíaPediatrics Department, Centro de Salud Laviada, Calle Juanín de Mieres, 8, 33207, Gijón, Spain. elisagarciagijon@gmail.com.ORCID 0000-0003-3515-7262
Mercedes Rodríguez-PérezMicrobiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
David Pérez-SolísPediatrics Department, Hospital Universitario San Agustín, Avilés, Spain.
Carlos Pérez-MéndezPediatrics Department, Hospital Universitario de Cabueñes, Gijón, Spain.
Cristina Molinos-NorniellaPediatrics Department, Hospital Universitario de Cabueñes, Gijón, Spain.
Ángeles Cobo-RuisánchezPediatrics Department, Centro de Salud Laviada, Calle Juanín de Mieres, 8, 33207, Gijón, Spain.
Eva María Fernández FernándezPediatrics Department, Hospital Carmen y Severo Ochoa., Cangas del Narcea, Spain.
Noelia García GonzálezPediatrics Department, Centro de Salud Teatinos, Oviedo, Spain.
Laura Calle-MiguelPediatrics Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Hospital Universitario Central de Asturias · ESHospital Universitario De Cabueñes · ESDepartamento de Salud · ESHospital Carmen y Severo Ochoa · ESHospital Universitario San Agustín · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUpdated seroprevalence estimates are important to describe the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) landscape and to guide public health decisions. The aims are to describe longitudinal changes in seroprevalence in children in a region in Northern Spain and to analyze factors associated with SARS-CoV-2 seropositivity.

methodsProspective multicenter longitudinal study with subjects recruited from July to September 2020. Children (up to 14 years old) were included and followed up until September 2021. Venous blood samples were collected every six months during three testing rounds and were analyzed for SARS-CoV-2 antibodies. The data regarding epidemiological features, contact tracing, symptoms, and virological tests were collected. The evolution of SARS-CoV-2 seroprevalence during the study and the differences between children with positive and negative SARS-CoV-2 antibody tests were analyzed.

resultsTwo hundred children were recruited (50.5% girls, median age 9.7 years). The overall seroprevalence increased from round 1 [1.5%, 95% confidence interval (CI) 0.3%-4.3%] to round 2 (9.1%, 95% CI 4.6%-12.7%) and round 3 (16.6%, 95% CI 9.5%-19.6%) (P < 0.001). Main changes occurred in children aged zero to four years (P = 0.001) who lived in urban areas (P < 0.001). None of the children who were previously positive became seronegative. Following multivariable analysis, three variables independently associated with SARS-CoV-2 seropositivity were identified: close contact with coronavirus disease 2019 (COVID-19) confirmed or suspected cases [odds ratio (OR) = 3.9, 95% CI 1.2-12.5], previous positive virological test (OR = 17.1, 95% CI 3.7-78.3) and fatigue (OR = 18.1, 95% CI 1.7-193.4).

conclusionsSARS-CoV-2 seroprevalence in children has remarkably increased during the time of our study. Fatigue was the only COVID-19-compatible symptom that was more frequent in seropositive than in seronegative children.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralChildFatigueFemaleHumansImmunoglobulin GLongitudinal StudiesMaleProspective StudiesSeroepidemiologic StudiesSpainAntibodies, ViralImmunoglobulin GAntibodiesChildCOVID-19Seroepidemiologic studies

Identifiers

PMID36169886
PMCPMC9514983
OpenAlexW4297328997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.